AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™ – Yahoo Finance

The Global CDMO’s Seattle site continues work on this new T1D treatment, the first and only treatment approved to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
SEATTLE, January 24, 2023–(BUSINESS WIRE)–AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site. The CDMO is producing TZIELD™ (teplizumab-mzwv), a new T1D treatment from Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases.
Provention Bio chose AGC Biologics to manufacture TZIELD after the CDMO helped guide the product through PPQ manufacturing and validation batches, and United States Food and Drug Administration (FDA) approval. More than 1.8 million Americans have T1D, an autoimmune disease caused by the destruction of beta cells. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older. Patients who progress to Stage 3 T1D will eventually require insulin injections for life.
"The multi-year process of shepherding a new therapy from clinical research to commercial launch requires the collaboration of multiple partners, and we are grateful for the ongoing strategic collaboration of AGC Biologics as we begin to deliver TZIELD to patients," said Provention Bio CEO Ashleigh Palmer. "This is an important milestone for the Type 1 Diabetes community, and we hope the launch of this therapy can truly make an impact on patients and families seeking innovative treatments for the delay of Stage 3 T1D."
AGC Biologics runs multiple mammalian cGMP manufacturing lines and a variety of scales at its Seattle facility. The campus serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes and houses a new microbial-based manufacturing line system. The AGC Biologics Seattle campus has produced biologics products for 30 years and has a long history of successful inspections by the FDA and commercial production.
"Congratulations to Provention Bio on this game-changing achievement for T1D patients," said Kevin Ingham, General Manager of AGC Biologics’ Seattle site. "We at AGC Biologics are proud to have helped develop this innovative new medicine and to be manufacturing it for commercial distribution. This achievement demonstrates our Seattle site’s increasing track record in commercial manufacturing, which is aligned with AGC Biologic’s purpose of bringing hope to life."
To learn more about AGC Biologics’ mammalian and microbial system-based biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle. For more information on the company’s Protein Biologics, Protein DNA (pDNA), Cell Therapy, Viral Vector and Messenger RNA (mRNA) drug product services visit www.agcbio.com.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including T1D, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005438/en/
Contacts
Nick McDonald
AGC Biologics
nmcdonald@agc.com
(425) 419-3555
Billionaire venture capitalist Mark Cuban has founded or invested early in hundreds of startup companies over the years. But only one of them, founded in January 2022, bears his name. The Mark Cuban Cost Plus Drug Co. seeks to disrupt the $365 billion U.S. prescription drug market, which is rife with pricing inefficiencies. For example, one tablet of the Type 2 diabetes treatment Metformin costs over $500 at retail prices. But through Cuban’s company, the same tablet is just $46.20. The company
Nothing will ruin a company's positive marketing flow like allegations of toxic chemicals or other health hazards. Iit happened, most recently, when an environmental health watchdog group sent a warning about elevated BPA chemicals in the sports bras produced by popular clothing makers like Nike , Gap -owned Athleta and Victoria's Secret . The latest major global brand to fall under chemical scrutiny is drinks giant Coca-Cola .
Amazon announces a new drug pass for Prime members.
Moderna and Pfizer have announced plans to quadruple the price of their COVID vaccines, putting them out of reach for millions. The U.S. should step in.
Amazon Pharmacy Chief Medical Officer Dr. Vin Gupta speaks with Yahoo Finance health care reporter Anjalee Khemlani about Amazon's new prescription drug plan, how it will work, and who it is meant for.
Axcella Health Inc (NASDAQ: AXLA) announced a regulatory path to the registration of AXA1125 for Long COVID Fatigue. The company received regulatory guidance from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA), supporting a single trial that could serve as the registration trial for patients with Long COVID fatigue. Axcella will meet with the MHRA soon to discuss the Innovative Licensing and Access Pathway (ILAP) application. The company submitted an Investigational New Dr
The new Prime membership benefit, dubbed RxPass, will offer unlimited access to commonly prescribed generic medications.
The agency appears to be aiming to make Covid-19 vaccination efforts resemble established influenza vaccination efforts.
The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.
Veracyte (NASDAQ: VCYT) and Exact Sciences (NASDAQ: EXAS) focus on genomic tests to diagnose various cancers. A report by BIS Research puts the molecular cancer diagnostics market at $4.1 billion in 2022 but with a compound annual growth rate (CAGR) of 11.4% through 2032, reaching a $12.1 billion market by that time. Cancer is formed by changes to the genome in a body's cells, leading to uncontrollable growth.
Doctors initially told Dave Whitford, 49, he was suffering from an inner ear infection caused by an insect bite
When managers are more open about their own mental health journey, experts say it can help create a more inclusive and supportive environment.
More than two years since announcing Amazon Pharmacy to take some of the prescription drugs business away from big (and smaller) drug stores, Amazon is launching a new product to expand its reach in the space. Today, it's taking the wraps off RxPass, a service where Prime users in the U.S. can pay a monthly flat fee of $5 to get as many generic versions of medications as they need. Amazon said that initially the service will cover generic drugs for 80 common ailments — they include, for example, Losartan (the generic for the hypertension drug Cozaar) and Sertraline (the generic for antidepressant Zoloft) and hair-growth pills — and it would not comment on its plans to expand the list.
Top healthcare stocks include Azenta for best value, Neurocrine Biosciences for fastest growth, and Signify Health for most momentum.
Bayer Aktiengesellschaft (OTC: BAYR.Y) and AstraZeneca (NASDAQ: AZN) are elite healthcare companies with shares that trade for less than $100 and make excellent long-term investments because of their revenue and earnings growth, promising pipelines, and above-average dividends. Bayer was down 11.2% in 2022 and currently trades for about $15 a share while AstraZeneca was up 16.4% in 2022 and currently trades for around $70 a share. Bayer is a huge German life science conglomerate.
Long COVID is having a significant effect on America’s workforce, preventing substantial numbers of people from going back to work while others continue needing medical care long after returning to their jobs, according to a new analysis of workers’ compensation claims in New York state. The study, published Tuesday by New York’s largest workers’ compensation insurer, found that during the first two years of the pandemic, about 71% of people the fund classified as experiencing long COVID either
The COVID-19 pandemic is continuing to take a toll on mental health nationwide.
Cipla Ltd. wants to make generic versions of Research Triangle Park drugmaker Fennec's lone product.
Amazon is adding a prescription drug discount program to its growing health care business. The retail giant said Tuesday that it will launch RxPass, a subscription service for customers who have Prime memberships. Amazon said people will pay $5 a month to fill as many prescriptions as they need from a list of about 50 generic medications, which are generally cheaper versions of brand-name drugs.
Clinical trials of lecanemab, to be marketed as Leqembi, have shown that it may modestly slow the pace of cognitive decline early in the disease.

source